Regulatory document
FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used…
FDA Safety Communications · Information · USA · Mar 24, 2015
Key facts
| Title | FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another Direct Acting Antiviral drug |
|---|---|
| Issuer | FDA Safety Communications |
| Source | FDA Safety Communications |
| Document type | Information |
| Country or region | USA |
| Date | Mar 24, 2015 |
| Document | fda.gov |
| Issuer website | fda.gov |
At a glance
- Yes Full text searchable in Orca1
- 100–999 Documents from this issuer in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Global regulations and guidance
Regulations, guidance and official notices from medical device and medicines regulators worldwide, collected by Orca1 from each issuer's website. Only the title, issuer, date and link are shown here; the full text is searchable in Orca1.
Source: Medical device and medicines regulators and agencies as named on each record (EMA, MHRA, TGA, CDSCO, PMDA, NMPA, Health Canada, HSA, the FDA and others), collected by Orca1 from each issuer's website · Source date: